The published overall survival statistics that I've read for 5 year survival are around 30% for metastatic prostate cancer that has spread to the bones. Since these statistics must be at least 5 years old, probably more like 7, I'm guessing that the patients in those statistics did not have second line ADT treatments Zytiga and Xtandi available to them. Just curious to know if someone has a guess as to what the new numbers would be with those second line drugs available or any other treatments that have become available since then. I would also appreciate it someone knows of any published literature on this subject and could point me to that. Thanks.